This is a summary of the European public assessment report (EPAR) for Rivastigmine Actavis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine Actavis.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Therapeutic Area (MeSH)
ATC Code
N06DA03
ATC Item
rivastigmine
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| rivastigmine hydrogen tartrate | N/A | Glycopyrronium Bromide/Rivastigmine |
EMA Name
Rivastigmine Actavis
Medicine Name
Rivastigmine Actavis
Aliases
N/ANo risk management plan link.
